From the Institute for Cardiovascular Prevention (IPEK), Ludwig-Maximilians-University, Munich, Germany (M.R., R.G-P., P.R., L.R., M.B., X.B., R.T.A.M., Y.D., O.S., C.W., A.S., S.S.).
Department of Pharmacology, Drug Development and Therapeutics and Turku University Hospital, University of Turku, Finland (P.R.).
Arterioscler Thromb Vasc Biol. 2018 May;38(5):1007-1019. doi: 10.1161/ATVBAHA.117.310536. Epub 2018 Mar 22.
Cardiovascular diseases and depression are the leading causes of disability in Western countries. Clinical data on potential cardiovascular effects of serotonin reuptake inhibitors (SSRIs), the most commonly used antidepressant drugs, are controversial. In addition to blocking serotonin reuptake transporter in the brain, SSRIs deplete the major peripheral serotonin (5-hydroxytryptamine [5-HT]) storage by inhibiting serotonin reuptake transporter-mediated uptake in platelets. In this study, we aimed to investigate the effect of chronic SSRI intake on the development of atherosclerosis.
Treatment of apolipoprotein E-deficient mice with the SSRI fluoxetine for 2, 4, or 16 weeks increased atherosclerotic lesion formation, with most pronounced effect during early plaque development. Intravital microscopy of carotid arteries revealed enhanced myeloid cell adhesion on fluoxetine treatment. Mechanistically, we found that fluoxetine augmented vascular permeability and increased chemokine-induced integrin-binding activity of circulating leukocytes. In vitro stimulation of murine blood demonstrated that fluoxetine, but not 5-HT, could directly promote β1 and β2 integrin activation provided C-C motif chemokine ligand 5 was also present. Similar effects were observed with the SSRI escitalopram. Enhanced C-C motif chemokine ligand 5-induced integrin activation by fluoxetine was also confirmed in a human neutrophil-like cell line. In contrast to the proatherogenic properties of fluoxetine, pharmacological inhibition of the peripheral 5-HT synthesizing enzyme tryptophan hydroxylase 1 did not promote atherosclerosis, suggesting that the proatherogenic effect of fluoxetine occurs independent of peripheral 5-HT depletion.
SSRI intake may promote atherosclerosis and therefore potentially increase the risk for acute cardiovascular events by a mechanism that is independent of 5-HT depletion.
心血管疾病和抑郁症是西方国家导致残疾的主要原因。关于 5-羟色胺再摄取抑制剂(SSRIs)——最常用的抗抑郁药——对心血管潜在影响的临床数据存在争议。除了阻断大脑中的 5-羟色胺再摄取转运体之外,SSRIs 通过抑制血小板中 5-羟色胺再摄取转运体介导的摄取来耗尽主要的外周 5-羟色胺(5-HT)储存。在这项研究中,我们旨在研究慢性 SSRIs 摄入对动脉粥样硬化发展的影响。
用 SSRIs 氟西汀治疗载脂蛋白 E 缺陷小鼠 2、4 或 16 周会增加动脉粥样硬化病变的形成,在早期斑块发展过程中效果最为明显。颈动脉的活体显微镜检查显示,氟西汀治疗会增强髓样细胞的黏附。从机制上讲,我们发现氟西汀增强了血管通透性,并增加了趋化因子诱导的循环白细胞的整合素结合活性。在体外刺激鼠血中发现,氟西汀(而非 5-HT)可以直接促进β1 和β2 整合素的激活,前提是也存在 C-C 基序趋化因子配体 5。SSRIs 依他普仑也观察到了类似的效果。在人中性粒细胞样细胞系中也证实了氟西汀增强 C-C 基序趋化因子配体 5 诱导的整合素激活。与氟西汀的促动脉粥样硬化特性相反,外周 5-HT 合成酶色氨酸羟化酶 1 的药理学抑制并没有促进动脉粥样硬化,这表明氟西汀的促动脉粥样硬化作用独立于外周 5-HT 耗竭。
SSRIs 的摄入可能会促进动脉粥样硬化的发展,从而通过一种独立于 5-HT 耗竭的机制增加急性心血管事件的风险。